|AHFS/Drugs.com||Consumer Drug Information|
|Chemical and physical data|
|Molar mass||75.0666 g/mol|
|3D model (Jmol)|
Acetohydroxamic acid (also known as AHA or Lithostat) is a drug that is a potent and irreversible inhibitor of bacterial and plant urease usually used for urinary tract infections. The molecule is similar to urea but is not hydrolyzable by the urease enzyme.
In 1983 the US Food and Drug Administration approved acetohydroxamic acid (AHA) as an orphan drug for "prevention of so-called struvite stones" under the newly enacted Orphan Drug Act of 1983. AHA cannot be patented because it is a standard chemical compound.
- W. Fishbein; P. Carbone (June 1965). "Urease catalysis. ii. Inhibition of the enzyme by hydroxyurea, hydroxylamine, and acetohydroxamic acid". J Biol Chem. 240: 2407–14.
- Marwick, Charles (1983). "New drugs selectively inhibit kidney stone formation". The Journal of the American Medical Association. 240 (3): 321–322. doi:10.1001/jama.1983.03340030003001.
|This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.|